Free tool
FAERS Monitor: Sovaldi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 204671 or its brand name (Sovaldi, Sofosbuvir). Reports on generic versions are filed under their own applications.
Reports
19,622
Serious
14,219
72% of reports
Hospitalization
4,454
Death reported
1,800
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue2,317
- drug ineffective1,931
- hepatitis c1,736
- headache1,646
- nausea1,398
- off label use1,389
- anaemia1,190
- insomnia1,065
- hepatocellular carcinoma911
- treatment failure837
- dyspnoea789
- asthenia781
- diarrhoea746
- dizziness716
- pruritus712
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 39 |
| 2014 | 3,690 |
| 2015 | 5,519 |
| 2016 | 4,033 |
| 2017 | 2,503 |
| 2018 | 1,579 |
| 2019 | 1,127 |
| 2020 | 353 |
| 2021 | 198 |
| 2022 | 195 |
| 2023 | 141 |
| 2024 | 139 |
| 2025 | 79 |
| 2026 | 23 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,034,537 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hepatitis cSignal | 1,736 | 179.8 | 171.2 | 264,360 |
| hepatocellular carcinomaSignal | 911 | 145.7 | 136.2 | 115,192 |
| treatment failureSignal | 837 | 10.9 | 10.2 | 7,494 |
| anaemiaSignal | 1,190 | 6.7 | 6.4 | 5,809 |
| insomniaSignal | 1,065 | 4.3 | 4.1 | 2,717 |
| fatigueSignal | 2,317 | 3.2 | 3.1 | 3,619 |
| headacheSignal | 1,646 | 2.8 | 2.7 | 1,984 |
| astheniaSignal | 781 | 2.2 | 2.1 | 536 |
| pruritus | 712 | 2.0 | 1.8 | 354 |
| nausea | 1,398 | 1.9 | 1.8 | 612 |
| off label use | 1,389 | 1.7 | 1.6 | 418 |
| drug ineffective | 1,931 | 1.6 | 1.5 | 427 |
| dizziness | 716 | 1.5 | 1.4 | 138 |
| dyspnoea | 789 | 1.5 | 1.4 | 132 |
| diarrhoea | 746 | 1.2 | 1.2 | 35 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.